

17 December 2024

AOTI, INC. (the "Company" or "Group" or "AOTI")

Grant of performance share awards to CFO under Long Term Incentive Plan

AOTI, INC., a medical technology group focused on the durable healing of wounds and prevention of amputations, announces that on 17th December 2024, the Company granted awards over ordinary shares in the form of nominal cost options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to Jayesh Pankhania, CFO, who joined AOTI in June 2024 and is a Person Discharging Managerial Responsibilities (PDMR), as detailed below:

PDMR	Role	Number of Performance Awards	Exercise Price ()
Jayesh Pankhania	Chief Financial Officer	208,333	0.00001

In determining the number of awards, the Company has used a share price of 132p, being the IPO price.

The Performance Awards will vest three years from the grant date conditional on meeting three-year performance conditions as described below.

40% of an award is subject to a revenue growth performance condition measured over a three-year period ending 31 December 2026.

30% of an award is subject to a relative total shareholder return (TSR) performance condition measured over three years from the date of the IPO. AOTI's TSR performance will be measured against a sector peer group of UK, US and other internationally quoted companies with 25% of this portion of the award vesting at median performance rising on a straight line to full vesting at upper quartile performance.

30% of an award is subject to an absolute total shareholder return performance condition measured over three years from the date of the IPO. Vesting will commence from zero at 10% compound annual growth rising on a straight line to full vesting at 20% compound annual growth.

END

AOTI, INC.

Dr. Mike Griffiths, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer

+44 (0)20 3727 1000
ir@aotinc.net

Peel Hunt LLP (Nominated Adviser and Broker)

Dr. Christopher Golden, Patrick Birkholm

+44 (0)20 7418 8900

FTI Consulting (Financial PR & IR)

Ben Atwell, Simon Conway,
Natalie Garland-Collins, Alex Davis

+44 (0)20 3727 1000
AOTI@fitconsulting.com

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂)[®] therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO₂[®] therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂[®] therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net

1.	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Jayesh Pankhania
b)	Reason for the nomination	

2.	Reason for the nomination	
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AOTI, INC.
b)	LEI	213800ZGCNDSTWIRK687
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument	Ordinary Shares
b)	Identification code	US03690C1027
c)	Nature of the transactions	Initial award under the AOTI LTIP
d)	Price(s) and volume(s)	Exercise Price: 0p per share Volume: 208,333
e)	Aggregated information - Aggregated volume - Price	As for d) above
f)	Date of the transactions	17 December 2024
f)	Place of the transactions	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFSLFELDLIS